| scholarly article | Q13442814 |
| P50 | author | Vittorio Pengo | Q42778559 |
| Domenico Prisco | Q43281338 | ||
| Ernesto Maddaloni | Q45346601 | ||
| Giuseppe Patti | Q37370554 | ||
| Francesca Santilli | Q59187601 | ||
| Raffaele De Caterina | Q87797284 | ||
| Mattia Galli | Q88332625 | ||
| Felicita Andreotti | Q89285015 | ||
| Giulia Renda | Q90250315 | ||
| Enrica Golia | Q114453010 | ||
| Vito Maurizio Parato | Q114453011 | ||
| Elisabetta Ricottini | Q114453012 | ||
| Working Group on Thrombosis of the Italian Society of Cardiology | Q114453013 | ||
| P2093 | author name string | Rossella Marcucci | |
| Ilaria Cavallari | |||
| Paolo Calabrò | |||
| Gentian Denas | |||
| Plinio Cirillo | |||
| Paola Simeone | |||
| P2860 | cites work | Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation | Q22305336 |
| Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies | Q24608301 | ||
| Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials | Q24645391 | ||
| Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke | Q24646522 | ||
| Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. | Q27687851 | ||
| Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study | Q28171078 | ||
| Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project | Q28176142 | ||
| Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus | Q28184127 | ||
| Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment | Q28185431 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events | Q28192726 | ||
| Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis | Q28193346 | ||
| Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus | Q28193753 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial | Q28209556 | ||
| Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial | Q28210537 | ||
| Platelet activation in type 2 diabetes mellitus | Q28210554 | ||
| Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy | Q28212833 | ||
| Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial | Q28218263 | ||
| A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women | Q28218670 | ||
| Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial | Q28219117 | ||
| Independent predictors of stroke in patients with atrial fibrillation: a systematic review | Q28219197 | ||
| The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study | Q28221353 | ||
| Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease | Q28222643 | ||
| The risk of venous thromboembolism is markedly elevated in patients with diabetes | Q28240788 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
| V.A. Cooperative Study of antiplatelet agents in diabetic patients after amputation for gangrene: unobserved, sudden, and unexpected deaths | Q28342185 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group | Q29619460 | ||
| Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials | Q30241829 | ||
| Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. | Q33501445 | ||
| Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials | Q33515541 | ||
| Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? | Q33585858 | ||
| Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial | Q34014586 | ||
| Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial | Q34021483 | ||
| 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres | Q34046881 | ||
| Rivaroxaban in patients with a recent acute coronary syndrome | Q34231902 | ||
| ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab | Q34368081 | ||
| Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial | Q34404150 | ||
| 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. | Q34538645 | ||
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
| Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Q34670462 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial | Q34751965 | ||
| Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study) | Q34921180 | ||
| The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study | Q35076036 | ||
| Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial | Q35195203 | ||
| Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation | Q35236071 | ||
| Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents | Q35783487 | ||
| Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. | Q35943907 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Venous thromboembolism in patients with diabetes mellitus | Q36178744 | ||
| Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease | Q36221940 | ||
| Old and new oral anticoagulants: Food, herbal medicines and drug interactions | Q36280465 | ||
| Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding | Q36308327 | ||
| Peripheral arterial disease in patients with diabetes | Q36413265 | ||
| Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study | Q36493505 | ||
| Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome | Q36807512 | ||
| Stroke in patients with diabetes. The Copenhagen Stroke Study | Q41015964 | ||
| Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
| Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. | Q41185286 | ||
| Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial | Q41234478 | ||
| Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes | Q42145594 | ||
| European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke | Q42551725 | ||
| Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes | Q42917068 | ||
| Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention | Q42932245 | ||
| Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co | Q43052182 | ||
| Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity | Q43238708 | ||
| Efficacy of aspirin for secondary prevention in patients with peripheral artery disease | Q43265096 | ||
| Association of aspirin use with major bleeding in patients with and without diabetes | Q43848353 | ||
| Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar | Q44056270 | ||
| IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi | Q44645484 | ||
| Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes | Q44802298 | ||
| Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease | Q44938343 | ||
| Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. | Q45045640 | ||
| Thromboxane biosynthesis and platelet function in type II diabetes mellitus | Q45056796 | ||
| High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. | Q45136309 | ||
| Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials | Q45139213 | ||
| The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation | Q45275091 | ||
| Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop | Q45305235 | ||
| Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. | Q45968266 | ||
| Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISM | Q46019314 | ||
| Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study | Q46068888 | ||
| Patients with peripheral arterial disease in the CHARISMA trial | Q46167781 | ||
| Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo | Q46214428 | ||
| Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. | Q46243509 | ||
| Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial | Q46336857 | ||
| A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. | Q46528728 | ||
| The direct effects of metformin on platelet function in vitro | Q46584886 | ||
| Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting St | Q46690785 | ||
| The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus | Q46810737 | ||
| Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial | Q46833339 | ||
| Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation | Q46921727 | ||
| Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects | Q46926316 | ||
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial | Q46938524 | ||
| Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial | Q47408050 | ||
| Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization | Q47742996 | ||
| Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus | Q47992848 | ||
| Anemia contributes to cardiovascular disease through reductions in nitric oxide | Q48328520 | ||
| 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. | Q49988607 | ||
| Randomised trial of prophylactic daily aspirin in British male doctors | Q36894287 | ||
| Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study | Q37074678 | ||
| The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. | Q37135995 | ||
| Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention | Q37177576 | ||
| Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study | Q37326883 | ||
| Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release | Q37386201 | ||
| Is diabetes a coronary risk equivalent? Systematic review and meta-analysis | Q37399487 | ||
| Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. | Q37786695 | ||
| Diabetes and antiplatelet therapy in acute coronary syndrome. | Q37846051 | ||
| Diabetes mellitus and thrombosis | Q37971199 | ||
| Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. | Q37996239 | ||
| Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence | Q38000088 | ||
| Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis | Q38133389 | ||
| Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome. | Q38170971 | ||
| Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin | Q38175225 | ||
| Management of venous thrombo-embolism: an update | Q38245422 | ||
| Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial | Q38384309 | ||
| Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study | Q38388438 | ||
| Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study | Q38394612 | ||
| Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial I | Q38396533 | ||
| Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial | Q38420837 | ||
| Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease | Q38493656 | ||
| On-treatment platelet reactivity: State of the art and perspectives. | Q38621049 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
| Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease | Q38917775 | ||
| Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. | Q38996955 | ||
| 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | Q39007236 | ||
| Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials | Q39060571 | ||
| Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease | Q39862463 | ||
| Prasugrel versus clopidogrel for acute coronary syndromes without revascularization | Q40058838 | ||
| Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack | Q40372807 | ||
| Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus | Q40580246 | ||
| Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. | Q40817339 | ||
| ??? | Q28220363 | ||
| Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus | Q50041299 | ||
| Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes | Q50093001 | ||
| Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. | Q50573978 | ||
| Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. | Q51061441 | ||
| Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity. | Q51629683 | ||
| Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (IS | Q51764221 | ||
| 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. | Q53038051 | ||
| SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes). | Q53097418 | ||
| Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. | Q53178855 | ||
| Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. | Q54704923 | ||
| Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. | Q55057248 | ||
| ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and | Q56680457 | ||
| Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA | Q57210299 | ||
| Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial | Q57278179 | ||
| Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus | Q57452495 | ||
| 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS | Q57621041 | ||
| Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease | Q57764459 | ||
| Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment | Q58420651 | ||
| Increased Platelet Aggregation in Early Diabetus Mellitus | Q66941531 | ||
| Pathogenesis of atherosclerosis in diabetes mellitus | Q67275665 | ||
| Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators | Q68021310 | ||
| Hepatic drug metabolism is increased in poorly controlled insulin-dependent diabetes mellitus | Q68628566 | ||
| Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus | Q72786073 | ||
| Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome | Q74265891 | ||
| Pharmacokinetics of clopidogrel after administration of a high loading dose | Q80371510 | ||
| Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation | Q80978609 | ||
| The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes | Q83797596 | ||
| Review article: Coagulation and fibrinolysis in diabetes | Q85040740 | ||
| Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease | Q85253139 | ||
| Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50 | Q86412065 | ||
| Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease | Q87447232 | ||
| Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism | Q87475330 | ||
| Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes | Q87660010 | ||
| Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) | Q88652909 | ||
| 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | Q89104948 | ||
| Antiplatelet therapy: Ticagrelor reduces cardiac events in patients with PAD or diabetes | Q89265267 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 113-130 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | Nature Reviews Cardiology | Q2108444 |
| P1476 | title | Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs | |
| P478 | volume | 16 |
| Q90860009 | Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand |
| Q91800897 | Effect of acute exposure in swiss mice (Mus musculus) to a fibrinolytic protease produced by Mucor subtilissimus UCP 1262: An histomorphometric, genotoxic and cytological approach |
| Q90177046 | Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention |
| Q90584919 | In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years |
| Q91301601 | Risk factors and predictive biomarkers of early cardiovascular disease in obese youth |
| Q91799459 | The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation |
Search more.